Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. submitted a Form 3 identifying Ramji Shiven as an officer with the title President Products & Tech. The filing does not report any share purchases, sales, or other transactions, and shows no derivative positions or holdings data in the provided summary.
Cellebrite DI Ltd. director Yonatan Domnitz filed an initial ownership report showing his equity position in the company. The filing lists 10,601 restricted stock units, each representing a contingent right to receive one ordinary share, vesting on September 17, 2026.
In addition, he holds 60,795 ordinary shares directly after the reported positions. The restricted stock units have an exercise price of $0.0000, indicating they are granted as equity compensation rather than purchased in the market. This Form 3 does not reflect new open-market buying or selling, but establishes his starting ownership as an insider.
Cellebrite DI Ltd. director Utsumi Ryusuke filed an initial statement of beneficial ownership. He reports direct holdings of 40,795 Ordinary Shares and 10,601 Restricted Stock Units, each representing a right to receive one Ordinary Share. The restricted stock units vest on September 17, 2026, reflecting future potential equity ownership rather than a current share issuance.
Cellebrite DI Ltd. Chief People Officer Tadmor-Eilat Zohar reported initial beneficial ownership of the company’s equity. She holds 129,814 Ordinary Shares directly, including multiple blocks of restricted share units and performance share units that vest over time based on service and performance conditions.
She also holds stock options over 22,722 Ordinary Shares at an exercise price of $4.95 per share expiring on February 13, 2033, and options over 28,236 Ordinary Shares at an exercise price of $11.51 per share expiring on March 19, 2034.
Cellebrite DI Ltd. director Troy Richardson filed an initial ownership report showing he holds 20,974 Ordinary Shares. This is a Form 3 filing, which establishes his starting stake as a company insider rather than reporting any new trade.
The position includes 10,601 Ordinary Shares represented by restricted share units granted on September 17, 2025, which are scheduled to vest on September 17, 2026. Each restricted unit converts into one Ordinary Share when it settles, so part of his reported holdings is still subject to future vesting.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan filed an initial ownership report showing significant equity holdings in the company. He directly holds 693,965 Ordinary Shares, including portions represented by restricted share units that were granted in 2025 and 2026 with vesting schedules extending through 2030.
Hogan also holds stock options over 1,000,000 Ordinary Shares and an additional 500,000 Ordinary Shares at an exercise price of $7.39 per share, expiring on August 6, 2033. Of the 1,000,000-share option grant, 625,000 options are already fully vested and exercisable, with the remainder vesting quarterly through August 7, 2027, while the 500,000-share option grant is fully vested and exercisable.
Cellebrite DI Ltd. executive Shavit Sigalit, the Chief Information Officer, reported her initial ownership position. She holds 82,738 Ordinary Shares directly, including time-based RSUs and performance share units that vest between May 2026 and February 2030, subject to service and performance conditions. She also holds stock options for 31,421 Ordinary Shares at an exercise price of $12.73 per share, expiring in August 2034, with a portion already vested and additional tranches vesting quarterly through August 2028.
Cellebrite DI Ltd. executive Armon Ronnen filed an initial statement of beneficial ownership, detailing his equity position in the company. As of March 18, 2026, he directly holds 277,844 Ordinary Shares, including shares represented by restricted share units and performance share units that vest over time and based on performance conditions.
Ronnen also holds several stock option grants over Ordinary Shares, including 60,606 underlying shares at an exercise price of $6.60 expiring on February 15, 2032, 80,808 underlying shares at $4.95 expiring on February 13, 2033, and two grants each covering 43,440 underlying shares at $11.51 expiring on March 19, 2034. Footnotes explain which portions are already fully vested and which will vest between May 14, 2026 and March 20, 2029, as well as performance-based awards tied to total shareholder return targets through March 20, 2028.
Cellebrite DI Ltd. director Nadine Baudot-Trajtenberg filed an initial Form 3 reporting her beneficial ownership in the company. She reports holding 35,554 Ordinary Shares directly. This total includes 10,601 Ordinary Shares represented by restricted share units granted on September 17, 2025, which vest on September 17, 2026.
Cellebrite DI Ltd. director Michael D. Capellas reported his initial holdings of 17,804 Ordinary Shares. This includes 9,494 Ordinary Shares represented by restricted share units granted on January 1, 2026, which are scheduled to vest on January 1, 2027, each RSU delivering one Ordinary Share upon settlement.